[go: up one dir, main page]

MX2018013744A - Metodos para clasificar pacientes con un cancer solido. - Google Patents

Metodos para clasificar pacientes con un cancer solido.

Info

Publication number
MX2018013744A
MX2018013744A MX2018013744A MX2018013744A MX2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A
Authority
MX
Mexico
Prior art keywords
methods
solid cancer
classifying patients
response
median
Prior art date
Application number
MX2018013744A
Other languages
English (en)
Other versions
MX393482B (es
Inventor
Galon Jérôme
Mlecnik Bernhard
Pages Franck
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2018013744A publication Critical patent/MX2018013744A/es
Publication of MX393482B publication Critical patent/MX393482B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos para clasificar pacientes que padecen un cáncer sólido, en particular a métodos para el pronóstico del tiempo de supervivencia de un paciente que padece un cáncer sólido y/o a métodos para evaluar el grado de respuesta de un paciente que padece un cáncer sólido al tratamiento antitumoral. El método se basa en la cuantificación de marcadores de respuesta inmunitaria múltiple y la determinación de a qué percentil de la distribución corresponden los valores cuando se comparan con una distribución de referencia. Cálculo de la media o la mediana de los percentiles determinados de los marcadores diferentes y comparación de este valor con un valor de referencia de la media o la mediana de percentiles, cuyo resultado se correlaciona con la supervivencia y el grado de respuesta.
MX2018013744A 2016-05-09 2017-05-09 Metodos para clasificar pacientes con un cancer solido MX393482B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (2)

Publication Number Publication Date
MX2018013744A true MX2018013744A (es) 2019-08-16
MX393482B MX393482B (es) 2025-03-24

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013744A MX393482B (es) 2016-05-09 2017-05-09 Metodos para clasificar pacientes con un cancer solido

Country Status (13)

Country Link
US (1) US20190309369A1 (es)
EP (1) EP3455631B1 (es)
JP (3) JP7281903B2 (es)
KR (1) KR102245021B1 (es)
CN (2) CN109690314B (es)
AU (1) AU2017261685B2 (es)
ES (1) ES2808004T3 (es)
MX (1) MX393482B (es)
PL (1) PL3455631T3 (es)
RU (1) RU2745730C2 (es)
SG (1) SG11201809317VA (es)
WO (1) WO2017194556A1 (es)
ZA (1) ZA201807020B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180357361A1 (en) 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
DK3746790T3 (da) * 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
FR3079617B1 (fr) 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
CN110988324B (zh) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 免疫状态确定系统、方法、装置及存储介质
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
EP4172628A1 (en) * 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
CN113174439B (zh) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
US20240210404A1 (en) * 2021-04-27 2024-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
KR20220155554A (ko) * 2021-05-13 2022-11-23 주식회사 센트릭스바이오 항-CD300c 항체를 이용한 병용 요법
CA3245129A1 (en) 2022-03-17 2023-09-21 Univ Paris Cite METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT
EP4533092A1 (en) * 2022-06-03 2025-04-09 Universita'Degli Studi di Roma "La Sapienza" Method for determining the prognostic score in patients with metastatic renal carcinoma
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
CN115747331B (zh) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN117476097B (zh) * 2023-10-25 2024-06-07 中山大学附属第六医院 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN119291200A (zh) * 2024-10-16 2025-01-10 华中科技大学同济医学院附属协和医院 一种用于检测cxcr4+cd8+t细胞用于预测肿瘤免疫治疗的检测试剂盒
CN120259410B (zh) * 2025-06-05 2025-09-23 北京大橡科技有限公司 基于双Panel多重生物标志物分析的肿瘤免疫响应可能性的评分方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521562A (ja) * 2003-03-07 2006-09-21 スレショルド ファーマシューティカルズ インコーポレイティッド 抗悪性腫瘍剤による治療に対する腫瘍の感受性を決定する方法
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
EP2619576B1 (en) * 2010-09-24 2020-06-10 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP2805165B1 (en) * 2012-01-20 2018-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the survival time of a patient suffering from a solid cancer based on density of b cells
AU2013276470B2 (en) * 2012-06-14 2018-06-07 Assistance Publique Hopitaux De Paris Method for quantifying immune cells in tumoral tissues and its applications
US11242564B2 (en) * 2012-07-12 2022-02-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
EP3470531A1 (en) * 2012-08-06 2019-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer
HK1211322A1 (en) * 2013-03-15 2016-05-20 昂考梅德药品有限公司 Methods of treating pancreatic cancer
WO2015007625A1 (en) * 2013-07-15 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer

Also Published As

Publication number Publication date
JP7281903B2 (ja) 2023-05-26
AU2017261685B2 (en) 2023-09-07
KR102245021B1 (ko) 2021-04-26
BR112018072993A8 (pt) 2022-11-08
EP3455631A1 (en) 2019-03-20
PL3455631T3 (pl) 2021-04-06
JP2022027788A (ja) 2022-02-14
ES2808004T3 (es) 2021-02-25
RU2018143409A (ru) 2020-06-10
RU2745730C2 (ru) 2021-03-31
US20190309369A1 (en) 2019-10-10
SG11201809317VA (en) 2018-11-29
BR112018072993A2 (pt) 2019-03-06
AU2017261685A1 (en) 2018-11-15
WO2017194556A1 (en) 2017-11-16
EP3455631B1 (en) 2020-06-24
JP7654318B2 (ja) 2025-04-01
MX393482B (es) 2025-03-24
CN115198018A (zh) 2022-10-18
CN109690314A (zh) 2019-04-26
ZA201807020B (en) 2020-05-27
RU2018143409A3 (es) 2020-06-29
KR20190016025A (ko) 2019-02-15
JP2019516979A (ja) 2019-06-20
JP2024019551A (ja) 2024-02-09
CN109690314B (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2018013744A (es) Metodos para clasificar pacientes con un cancer solido.
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MX2018010362A (es) Metodos y sistemas para evaluar carga mutacional de tumores.
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
MX2022003273A (es) Anticuerpos anti-tau y metodos de uso.
CO2017013446A2 (es) Composiciones que comprenden cepas bacterianas del género bacteroides
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX388405B (es) Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
MX2021014367A (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
TWD173737S (zh) 肌肉鍛鍊機器
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
CY1124706T1 (el) Συνδυασμοι και χρησεις αυτων
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX382410B (es) Determinación de niveles de glicosaminoglicanos mediante espectrometría de masas.
MX2017007117A (es) Composicion acuosa de revestimiento y proceso de la misma.
LT3442547T (lt) Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai
MX2019006005A (es) Metodos para la deteccion de cancer.
MX388890B (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
EA201791491A1 (ru) Способы выделения тромбоцитов
IL272810A (en) Methods for diagnosing and treating lung cancer
MX2019002430A (es) Agente antitumoral, mejorador del efecto antitumoral, y kit antitumoral.